Mohammad K Hararah1, William A Stokes2, Ayman Oweida3, Tejas Patil4, Arya Amini5, Julie Goddard1, Daniel W Bowles4,6, Sana D Karam3. 1. Department of Otolaryngology, University of Colorado School of Medicine, Aurora, U.S.A. 2. Department of Radiation Oncology, Emory University, Atlanta, Georgia, U.S.A. 3. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, U.S.A. 4. Department of Medical Oncology, University of Colorado School of Medicine, Aurora, U.S.A. 5. Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California, U.S.A. 6. Eastern Colorado Health Care System, Department of Veterans Affairs, Denver, Colorado, U.S.A.
Abstract
OBJECTIVE: Management of tracheal squamous cell carcinoma (TSCC) has been complicated by the lack of prognostic data and staging. We describe the epidemiology of TSCC and current treatment approaches. METHODS: Five hundred thirty-two adult patients with primary TSCC from 2004 to 2012 in the National Cancer Database were identified. Demographic, clinical factors, and 5-year overall survival were analyzed. Staging was classified as localized, regional extension, and distant spread. Treatment modality was defined as "no treatment (NT)," "limited surgery (LS)," "curative surgery (CS)," "LS with any adjuvant therapy (AT) (LS+AT)," "CS with AT (CS+AT)," "radiation therapy (RT)," or "chemoradiation (CRT)." RESULTS: Overall survival was 25%. Majority of cases were males, white, and occurred in sixth/seventh decades. Twenty-six percent of cases received CRT, 20% underwent LS+AT or CS+AT, 20% underwent LS or CS only, and 17% underwent RT alone. On multivariate analysis, CS (HR 0.42, 95% CI: 0.26-0.69), CS+AT (HR 0.44, 95% CI: 0.36-0.77), CRT (HR 0.48, 95% CI: 0.35-0.67), and RT (HR, 0.66 95% CI: 0.46-0.94) were associated with decreased likelihood of death compared to NT. Elderly patients and those with poor performance status had worse outcomes even on multivariate analysis. CONCLUSIONS: TSCC is increasingly treated with surgery and systemic therapy in addition to RT, with improved survival outcomes. CS, CS+AT, CRT, or RT provided improved survival advantage in patients with variable levels of improvement based on the extent of the disease. Prospective trials would help differentiate survival advantages between treatment modalities. Patients' goals of care, comorbidities, and age should be considered when deciding appropriate treatment recommendations. LEVEL OF EVIDENCE: NA Laryngoscope, 130:405-412, 2020.
OBJECTIVE: Management of tracheal squamous cell carcinoma (TSCC) has been complicated by the lack of prognostic data and staging. We describe the epidemiology of TSCC and current treatment approaches. METHODS: Five hundred thirty-two adult patients with primary TSCC from 2004 to 2012 in the National Cancer Database were identified. Demographic, clinical factors, and 5-year overall survival were analyzed. Staging was classified as localized, regional extension, and distant spread. Treatment modality was defined as "no treatment (NT)," "limited surgery (LS)," "curative surgery (CS)," "LS with any adjuvant therapy (AT) (LS+AT)," "CS with AT (CS+AT)," "radiation therapy (RT)," or "chemoradiation (CRT)." RESULTS: Overall survival was 25%. Majority of cases were males, white, and occurred in sixth/seventh decades. Twenty-six percent of cases received CRT, 20% underwent LS+AT or CS+AT, 20% underwent LS or CS only, and 17% underwent RT alone. On multivariate analysis, CS (HR 0.42, 95% CI: 0.26-0.69), CS+AT (HR 0.44, 95% CI: 0.36-0.77), CRT (HR 0.48, 95% CI: 0.35-0.67), and RT (HR, 0.66 95% CI: 0.46-0.94) were associated with decreased likelihood of death compared to NT. Elderly patients and those with poor performance status had worse outcomes even on multivariate analysis. CONCLUSIONS: TSCC is increasingly treated with surgery and systemic therapy in addition to RT, with improved survival outcomes. CS, CS+AT, CRT, or RT provided improved survival advantage in patients with variable levels of improvement based on the extent of the disease. Prospective trials would help differentiate survival advantages between treatment modalities. Patients' goals of care, comorbidities, and age should be considered when deciding appropriate treatment recommendations. LEVEL OF EVIDENCE: NA Laryngoscope, 130:405-412, 2020.
Authors: Henning A Gaissert; Hermes C Grillo; M Behgam Shadmehr; Cameron D Wright; Manjusha Gokhale; John C Wain; Douglas J Mathisen Journal: Ann Thorac Surg Date: 2004-12 Impact factor: 4.330
Authors: Jimmie Honings; Jos A A M van Dijck; Ad F T M Verhagen; Henricus F M van der Heijden; Henri A M Marres Journal: Ann Surg Oncol Date: 2006-12-02 Impact factor: 5.344
Authors: S Mahmoud Nouraei; Steve E Middleton; S A Reza Nouraei; Jagdeep S Virk; P Jeremy George; Martin Hayward; Guri S Sandhu Journal: Laryngoscope Date: 2013-07-19 Impact factor: 3.325
Authors: Jimmie Honings; Henning A Gaissert; Ad F T M Verhagen; Jos A A M van Dijck; Henricus F M van der Heijden; Lya van Die; Johan Bussink; Johannes H A M Kaanders; Henri A M Marres Journal: Ann Surg Oncol Date: 2008-11-27 Impact factor: 5.344
Authors: Jiagen Li; Fengwei Tan; Yalong Wang; Qi Xue; Yushun Gao; Juwei Mu; Yousheng Mao; Jun Zhao; Dali Wang; Xiaoli Feng; Susheng Shi; Kenichi Suda; Giuseppe Cardillo; Luca Bertolaccini; Maurizio V Infante; Paul E Van Schil; Shugeng Gao; Jie He Journal: Transl Lung Cancer Res Date: 2022-05